GlassScriptPhysician profile
Charles Williamson
NPI 1396740122
$16,107.19
in general payments reported to CMS, 2019-2025
24 companies · $6,511 in 2025
The $6,511 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $1,199 · 2021: $258 · 2022: $467 · 2023: $5,477 · 2024: $893 · 2025: $6,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,600 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,240 · Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,239.84 |
| Food and Beverage | $2,041.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $6,048.59 | 2019-2025 | Travoprost Intraocular Implant - Idose, Idose |
| Abbvie INC. | $5,496.09 | 2022-2025 | |
| Allergan, INC. | $1,595.35 | 2019-2022 | |
| Alcon Vision LLC | $570.55 | 2019-2025 | Wavelight Refractive Suite, Wavelight Ex500 Excimer Laser, Lensx |
| Bausch & Lomb Americas INC. | $300.46 | 2023-2025 | Envista Mx60 Iol, Miebo, Envista Envy Iol |
| Sun Pharmaceutical Industries INC. | $281.17 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $204.33 | 2019-2025 | Tecnis Iol, Catalys System |
| Staar Surgical Company | $185.17 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $163.60 | 2019-2021 | |
| Microsurgical Technology, INC. | $163.10 | 2025 | |
| Optos, INC. | $137.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $133.94 | 2019-2023 | |
| Biotissue Holdings INC. | $129.29 | 2025 | |
| Harrow Eye, LLC | $124.27 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $117.45 | 2025 | Acthar |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $116.95 | 2024 | Oxervate |
| Tearlab Corp | $83.20 | 2023 | Tearlab Osmolarity System |
| Lensar, INC. | $78.23 | 2022 | |
| Ivantis, INC | $77.19 | 2021 | |
| New World Medical,INC. | $33.13 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $18.18 | 2022 | |
| Aerie Pharmaceuticals, INC. | $17.30 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $16.21 | 2021 | |
| Kala Pharmaceuticals, INC. | $15.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.